---
title: "Pre-market hot trades in US stocks: Check Cap pre-market down 17.65%; Pasithea Therapeutics pre-market down 14.29%"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/268043307.md"
description: "Check Cap pre-market down 17.65%; Pasithea Therapeutics pre-market down 14.29%; Direct Digital pre-market up 71.88%; Webuy Global pre-market up 50.00%; Republic Power pre-market up 28.40%"
datetime: "2025-12-01T09:11:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/268043307.md)
  - [en](https://longbridge.com/en/news/268043307.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/268043307.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/268043307.md) | [繁體中文](https://longbridge.com/zh-HK/news/268043307.md)


# Pre-market hot trades in US stocks: Check Cap pre-market down 17.65%; Pasithea Therapeutics pre-market down 14.29%

**Pre-market Hot Trades in US Stocks**

Check Cap, down 17.65% in pre-market, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation.

Pasithea Therapeutics down 14.29% in pre-market. Based on recent news,

1.  On November 29, Pasithea Therapeutics announced it would raise $60 million through a public offering of 80 million shares of common stock at a price of $0.75 per share. This move aims to ensure the company can operate until the first half of 2028 and advance the research and clinical trials of its cancer treatment drug PAS-004. After the news was announced, the stock price briefly rose nearly 60% but then fell back.
    
2.  On November 28, the company announced that its developing drug PAS-004 might not achieve the statistical significance required for regulatory approval, increasing uncertainty for investors and leading to stock price volatility.
    
3.  On November 28, the company stated it would continue to pursue potential acquisition or licensing deals to support its long-term development plans. Although this news indicates the company's intention to expand its business, market reactions have been mixed, leading to increased stock price volatility. The biopharmaceutical industry has been highly volatile recently, and investors should exercise caution.
    

**Top Gainers in Pre-market US Stocks**

Direct Digital, up 71.88% in pre-market, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation.

Webuy Global up 50% in pre-market. Based on recent key news:

1.  On November 28, Webuy Global released an important announcement on the EDGAR system of the U.S. Securities and Exchange Commission. This announcement sparked positive expectations in the market regarding the company's future development, driving the stock price up significantly by 50% in pre-market. Source: EDGAR system
    
2.  No other significant news recently.
    
3.  No other significant news recently. High attention in Hong Kong and U.S. markets.
    

Republic Power, up 28.40% in pre-market, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation

### 相关股票

- [Check Cap (MBAI.US)](https://longbridge.com/zh-CN/quote/MBAI.US.md)
- [Pasithea Therapeutics (KTTA.US)](https://longbridge.com/zh-CN/quote/KTTA.US.md)

## 相关资讯与研究

- [Check-Cap Highlights MBody AI’s Expanded Fortune 500 Robotics Deployment Ahead of Merger](https://longbridge.com/zh-CN/news/281235217.md)
- [MindBio Announces Closing of Private Placement](https://longbridge.com/zh-CN/news/281416173.md)
- [BullFrog AI Signs Major AI Drug Discovery Partnership](https://longbridge.com/zh-CN/news/281092205.md)
- [14:37 ETLevrx and Waltz Health Partner to Expand Access to Transparent Pharmacy Pricing](https://longbridge.com/zh-CN/news/281411704.md)
- [TippingPoint Biosciences Raises $4.5M Seed to Drug Hidden Epigenetic Targets in Deadly Pediatric Brain Cancer](https://longbridge.com/zh-CN/news/281175947.md)